New River keeps buy rating from Merrill

New River Pharmaceuticals Inc. was maintained at its buy rating by Merrill Lynch analyst David Munno. Shire announced that a U.S. federal judge set an Oct. 30 trial date, four to six months later than the analyst expected to hear the patent infringement with Barr on generic Adderall XR. The later trial gives Shire and New River time to transition patients to NRP104 from Adderall XR. Also, New River announced uneventful fourth-quarter 2005 earnings results. Shares of the Radford, Va., pharmaceutical company were up $1.50, or 4.80%, at $32.75 on volume of 293,221 shares versus the three-month running average of 272,941 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.